Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Prognostic value of CD117 in cancer: a meta-analysis
Fuyou Zhao1, Yuqing Chen2, Qiong Wu1
1Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui 233000, China.
Background:
The prognostic value of CD117 expression in cancers has been evaluated for several years while the results remain controversial. We thus performed a systematic review and meta-analysis of studies assessing the impact of CD117 expression on overall survival (OS) and disease-free survival (DFS) to clarify this issue.
Methods:
We searched Pubmed, Embase and Web of Science to identify studies on the prognostic impact of CD117 expression in cancers. A total of 4,458 patients from 39 eligible studies were included in the analysis. Pooled risk ratios (RRs) with 95% confidence interval (95% CI) were calculated to estimate the effect using random-effects model.
Results:
The analysis indicated that CD117 had significant association with poor OS of osteosarcoma (OR=1.36, 95% CI=1.03-1.79, I2=0%, fixed model) and renal carcinoma (OR=4.86, 95% CI=2.72-8.67, I2=0%, fixed model).However, no significant association between CD117 and DFS was found in overall studies.
Conclusions:
CD117 expression might be a predictive factor of poor prognosis in some surgically treated cancers, particularly in renal carcinoma.
Related Concept Videos
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...